Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127692101 | 12769210 | 1 | I | 20160915 | 20160921 | 20160921 | PER | US-SHIRE-US201612974 | SHIRE | 0.00 | F | Y | 77.98000 | KG | 20160921 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127692101 | 12769210 | 1 | PS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | 20 MG, 1X/DAY:QD | 21977 | 20 | MG | CAPSULE | QD | ||||||
| 127692101 | 12769210 | 2 | C | FLUOXETINE | FLUOXETINE HYDROCHLORIDE | 1 | Unknown | UNK, UNKNOWN | D | 0 | |||||||||
| 127692101 | 12769210 | 3 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | Unknown | UNK, UNKNOWN | D | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127692101 | 12769210 | 1 | Attention deficit/hyperactivity disorder |
| 127692101 | 12769210 | 2 | Product used for unknown indication |
| 127692101 | 12769210 | 3 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127692101 | 12769210 | Headache |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127692101 | 12769210 | 1 | 20160908 | 0 |